About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 780436, 11 pages
http://dx.doi.org/10.1155/2012/780436
Review Article

Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus

1Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, The University of Chicago, Chicago, IL 60637, USA
2Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA

Received 21 June 2012; Revised 31 August 2012; Accepted 12 September 2012

Academic Editor: Shervin Assassi

Copyright © 2012 Candace M. Cham et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Hochberg, “Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 9, p. 1725, 1997. View at Scopus
  2. D. Alarcón-Segovia, M. E. Alarcón-Riquelme, M. H. Cardiel et al., “Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1138–1147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Rhodes and T. J. Vyse, “The genetics of SLE: an update in the light of genome-wide association studies,” Rheumatology, vol. 47, no. 11, pp. 1603–1611, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Tsokos, “Systemic lupus erythematosus,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2110–2121, 2011.
  5. P. Blanco, A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau, “Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus,” Science, vol. 294, no. 5546, pp. 1540–1543, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. T. B. Niewold, D. N. Clark, R. Salloum, and B. D. Poole, “Interferon alpha in systemic lupus erythematosus,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 948364, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kim, Y. Kanayama, N. Negoro, M. Okamura, T. Takeda, and T. Inoue, “Serum levels of interferons in patients with systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 70, no. 3, pp. 562–569, 1987. View at Scopus
  8. T. B. Niewold, J. Hua, T. J. A. Lehman, J. B. Harley, and M. K. Crow, “High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus,” Genes and Immunity, vol. 8, no. 6, pp. 492–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. C. E. Weckerle, B. S. Franek, J. A. Kelly et al., “Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 63, no. 4, pp. 1044–1053, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. C. Baechler, F. M. Batliwalla, G. Karypis et al., “Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2610–2615, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Bennett, A. K. Palucka, E. Arce et al., “Interferon and granulopoiesis signatures in systemic lupus erythematosus blood,” Journal of Experimental Medicine, vol. 197, no. 6, pp. 711–723, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. G. M. Han, S. L. Chen, N. Shen, S. Ye, C. D. Bao, and Y. Y. Gu, “Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray,” Genes and Immunity, vol. 4, no. 3, pp. 177–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Ishii, H. Onda, A. Tanigawa et al., “Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients,” DNA Research, vol. 12, no. 6, pp. 429–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. A. Kirou, C. Lee, S. George et al., “Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3958–3967, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Ko, B. S. Franek, M. Marion, K. M. Kaufman, C. D. Langefeld, and J. B. Harley, “Genetic ancestry, serum interferon-alpha activity, and autoantibodies in systemic lupus erythematosus,” Journal of Rheumatology, vol. 39, no. 6, pp. 1238–1240, 2012.
  16. T. B. Niewold, J. E. Adler, S. B. Glenn, T. J. A. Lehman, J. B. Harley, and M. K. Crow, “Age- and sex-related patterns of serum interferon-α activity in lupus families,” Arthritis and Rheumatism, vol. 58, no. 7, pp. 2113–2119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. E. Ronnblom, K. E. Oberg, and G. V. Alm, “Possible induction of systemic lupus erythematosus by interferon α-treatment in a patient with a malignant carcinoid tumour,” Journal of Internal Medicine, vol. 227, no. 3, pp. 207–210, 1990. View at Scopus
  18. T. B. Niewold and W. I. Swedler, “Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C,” Clinical Rheumatology, vol. 24, no. 2, pp. 178–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. B. Niewold, “Interferon alpha-induced lupus: proof of principle,” Journal of Clinical Rheumatology, vol. 14, no. 3, pp. 131–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. B. J. Barnes, P. A. Moore, and P. M. Pitha, “Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon α genes,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 23382–23390, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Sigurdsson, G. Nordmark, H. H. H. Göring et al., “Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus,” American Journal of Human Genetics, vol. 76, no. 3, pp. 528–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. R. Graham, S. V. Kozyrev, E. C. Baechler et al., “A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus,” Nature Genetics, vol. 38, no. 5, pp. 550–555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. R. R. Graham, C. Kyogoku, S. Sigurdsson et al., “Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 16, pp. 6758–6763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. D. Shin, Y. K. Sung, C. B. Choi, S. O. Lee, H. W. Lee, and S. C. Bae, “Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population,” Arthritis Research and Therapy, vol. 9, article R32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. V. P. L. Reddy, R. Velázquez-Cruz, V. Baca et al., “Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygozity than Europeans,” Human Genetics, vol. 121, no. 6, pp. 721–727, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Kawasaki, C. Kyogoku, J. Ohashi et al., “Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms,” Arthritis and Rheumatism, vol. 58, no. 3, pp. 826–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Kelly, J. M. Kelley, K. M. Kaufman et al., “Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans,” Genes and Immunity, vol. 9, no. 3, pp. 187–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Sigurdsson, H. H. H. Göring, G. Kristjansdottir et al., “Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus,” Human Molecular Genetics, vol. 17, no. 6, pp. 872–881, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. H. O. Siu, W. Yang, C. S. Lau et al., “Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese,” Journal of Rheumatology, vol. 35, no. 2, pp. 360–362, 2008. View at Scopus
  30. G. Hom, R. R. Graham, B. Modrek et al., “Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX,” New England Journal of Medicine, vol. 358, no. 9, pp. 900–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Gateva, J. K. Sandling, G. Hom et al., “A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus,” Nature Genetics, vol. 41, no. 11, pp. 1228–1233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. W. Han, H. F. Zheng, Y. Cui, L. D. Sun, D. Q. Ye, and Z. Hu, “Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus,” Nature Genetics, vol. 41, no. 11, pp. 1234–1237, 2009.
  33. T. M. Jarvinen, A. Hellquist, M. Zucchelli, S. Koskenmies, J. Panelius, and T. Hasan, “Replication of GWAS-identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population,” Rheumatology, vol. 51, no. 1, pp. 87–92, 2012.
  34. G. B. Nordang, M. K. Viken, S. S. Amundsen, E. S. Sanchez, B. Flato, and O. T. Forre, “Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts,” Rheumatology, vol. 51, no. 4, pp. 619–626, 2012.
  35. N. Nelson, M. S. Marks, P. H. Driggers, and K. Ozato, “Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription,” Molecular and Cellular Biology, vol. 13, no. 1, pp. 588–599, 1993. View at Scopus
  36. C. R. Escalante, J. Yie, D. Thanos, and A. K. Aggarwal, “Structure of IRF-1 with bound DNA reveals determinants of interferon regulation,” Nature, vol. 391, no. 6662, pp. 103–106, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Santana-de Anda, D. Gomez-Martin, M. Diaz-Zamudio, and J. Alcocer-Varela, “Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology,” Autoimmunity Reviews, vol. 11, no. 2, pp. 98–103, 2011.
  38. S. E. Sweeney, “Targeting interferon regulatory factors to inhibit activation of the type I IFN response: implications for treatment of autoimmune disorders,” Cellular Immunology, vol. 271, no. 2, pp. 342–349, 2011.
  39. T. Krausgruber, K. Blazek, T. Smallie et al., “IRF5 promotes inflammatory macrophage polarization and T H1-TH17 responses,” Nature Immunology, vol. 12, no. 3, pp. 231–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. V. Kozyrev and M. E. Alarcon-Riquelme, “The genetics and biology of Irf5-mediated signaling in lupus,” Autoimmunity, vol. 40, no. 8, pp. 591–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. B. J. Barnes, M. J. Kellum, A. E. Field, and P. M. Pitha, “Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes,” Molecular and Cellular Biology, vol. 22, no. 16, pp. 5721–5740, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Taniguchi, K. Ogasawara, A. Takaoka, and N. Tanaka, “IRF family of transcription factors as regulators of host defense,” Annual Review of Immunology, vol. 19, pp. 623–655, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Kawasaki, T. Kawai, and S. Akira, “Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity,” Immunological Reviews, vol. 243, no. 1, pp. 61–73, 2011.
  44. T. F. Cheng, S. Brzostek, O. Ando, S. Van Scoy, K. P. Kumar, and N. C. Reich, “Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection,” Journal of Immunology, vol. 176, no. 12, pp. 7462–7470, 2006. View at Scopus
  45. A. Schoenemeyer, B. J. Barnes, M. E. Mancl et al., “The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17005–17012, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Takaoka, H. Yanai, S. Kondo et al., “Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors,” Nature, vol. 434, no. 7030, pp. 243–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kawai, S. Sato, K. J. Ishii et al., “Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6,” Nature Immunology, vol. 5, no. 10, pp. 1061–1068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Y. Balkhi, K. A. Fitzgerald, and P. M. Pitha, “Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination,” Molecular and Cellular Biology, vol. 28, no. 24, pp. 7296–7308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Deng, C. Wang, E. Spencer et al., “Activation of the Iκb kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain,” Cell, vol. 103, no. 2, pp. 351–361, 2000. View at Scopus
  50. D. Feng, N. Sangster-Guity, R. Stone et al., “Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression,” Journal of Immunology, vol. 185, no. 10, pp. 6003–6012, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Baccala, K. Hoebe, D. H. Kono, B. Beutler, and A. N. Theofilopoulos, “TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity,” Nature Medicine, vol. 13, no. 5, pp. 543–551, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. W. C. Au, W. S. Yeow, and P. M. Pitha, “Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3,” Virology, vol. 280, no. 2, pp. 273–282, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Lin, Y. Mamane, and J. Hiscott, “Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains,” Molecular and Cellular Biology, vol. 19, no. 4, pp. 2465–2474, 1999. View at Scopus
  54. H. C. Chang Foreman, S. Van Scoy, T. F. Cheng, and N. C. Reich, “Activation of interferon regulatory factor 5 by site specific phosphorylation,” PloS ONE, vol. 7, no. 3, Article ID e33098, 2012.
  55. W. Chen, S. S. Lam, H. Srinath et al., “Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5,” Nature Structural and Molecular Biology, vol. 15, no. 11, pp. 1213–1220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Lin, L. Yang, M. Arguello, C. Penafuerte, and J. Hiscott, “A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization,” Journal of Biological Chemistry, vol. 280, no. 4, pp. 3088–3095, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. B. J. Barnes, A. E. Field, and P. M. Pitha-Rowe, “Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 16630–16641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. C. M. Pickart and D. Fushman, “Polyubiquitin chains: polymeric protein signals,” Current Opinion in Chemical Biology, vol. 8, no. 6, pp. 610–616, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. J. E. Hutti, B. E. Turk, J. M. Asara, A. Ma, L. C. Cantley, and D. W. Abbott, “IκB kinase β phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-κB pathway,” Molecular and Cellular Biology, vol. 27, no. 21, pp. 7451–7461, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. E. Mancl, G. Hu, N. Sangster-Guity et al., “Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms: multiple isoforms with distinct cell type-specific expression, localization, regulation, and function,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21078–21090, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. I. Nusinzon and C. M. Horvath, “Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation,” Science's STKE, vol. 2005, no. 296, article re11, 2005. View at Scopus
  62. A. Caillaud, A. Prakash, E. Smith et al., “Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49417–49421, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Masumi, Y. Yamakawa, H. Fukazawa, K. Ozato, and K. Komuro, “Interferon regulatory factor-2 regulates cell growth through its acetylation,” Journal of Biological Chemistry, vol. 278, no. 28, pp. 25401–25407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. T. B. Niewold, J. A. Kelly, S. N. Kariuki, B. S. Franek, A. A. Kumar, and K. M. Kaufman, “IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 71, no. 3, pp. 463–468, 2012.
  65. S. V. Kozyrev, S. Lewén, P. M. V. L. Reddy et al., “Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 56, no. 4, pp. 1234–1241, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. D. S. C. Graham, H. Manku, S. Wagner et al., “Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation,” Human Molecular Genetics, vol. 16, no. 6, pp. 579–591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Wen, S. M. Ellingson, C. Kyogoku, E. J. Peterson, and P. M. Gaffney, “Exon 6 variants carried on systemic lupus erythematosus (SLE) risk haplotypes modulate IRF5 function,” Autoimmunity, vol. 44, no. 2, pp. 82–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. T. B. Niewold, J. A. Kelly, M. H. Flesch, L. R. Espinoza, J. B. Harley, and M. K. Crow, “Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2481–2487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Feng, R. C. Stone, M. L. Eloranta et al., “Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 562–573, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. O. J. Rullo, J. M. P. Woo, H. Wu et al., “Association of IRF5 polymorphisms with activation of the interferon α pathway,” Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 611–617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Richez, K. Yasuda, R. G. Bonegio et al., “IFN regulatory factor 5 is required for disease development in the FcγRIIB-/-Yaa and FcγRIIB-/- mouse models of systemic lupus erythematosus,” Journal of Immunology, vol. 184, no. 2, pp. 796–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. D. A. Savitsky, H. Yanai, T. Tamura, T. Taniguchi, and K. Honda, “Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 22, pp. 10154–10159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Lien, C. M. Fang, D. Huso, F. Livak, R. Lu, and P. M. Pitha, “Critical role of IRF-5 in regulation of B-cell differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 10, pp. 4664–4668, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. T. B. Niewold, T. L. Rivera, J. P. Buyon, and M. K. Crow, “Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 541–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. T. S. Cherian, S. N. Kariuki, B. S. Franek, J. P. Buyon, R. M. Clancy, and T. B. Niewold, “IRF5 SLE-risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in neonatal lupus mothers,” Arthritis and Rheumatism, vol. 64, no. 10, pp. 3383–3387, 2012.
  76. R. Salloum and T. B. Niewold, “Interferon regulatory factors in human lupus pathogenesis,” Translational Research, vol. 157, no. 6, pp. 326–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Robinson, S. N. Kariuki, B. S. Franek, M. Kumabe, A. A. Kumar, and M. Badaracco, “Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients,” Journal of Immunology, vol. 187, no. 3, pp. 1298–1303, 2011.
  78. J. Pothlichet, T. B. Niewold, D. Vitour, B. Solhonne, M. K. Crow, and M. Si-Tahar, “A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients,” EMBO Molecular Medicine, vol. 3, no. 3, pp. 142–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Salloum, B. S. Franek, S. N. Kariuki et al., “Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-α activity in lupus patients,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 553–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Agik, B. S. Franek, A. A. Kumar, M. Kumabe, T. O. Utset, and R. A. Mikolaitis, “The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes,” Journal of Immunology, vol. 39, no. 1, pp. 73–78, 2012.
  81. T. B. Niewold, “Interferon alpha as a primary pathogenic factor in human lupus,” Journal of Interferon & Cytokine Research, vol. 31, no. 12, pp. 887–892, 2011.
  82. S. N. Kariuki, B. S. Franek, A. A. Kumar et al., “Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 12, no. 4, article R151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Deng and B. P. Tsao, “Genetic susceptibility to systemic lupus erythematosus in the genomic era,” Nature Reviews Rheumatology, vol. 6, no. 12, pp. 683–692, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. G. S. Garcia-Romo, S. Caielli, B. Vega et al., “Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus,” Science Translational Medicine, vol. 3, no. 73, Article ID 73ra20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Lande, D. Ganguly, V. Facchinetti et al., “Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus,” Science Translational Medicine, vol. 3, no. 73, Article ID 73ra19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. E. J. Hennessy, A. E. Parker, and L. A. J. O'Neill, “Targeting Toll-like receptors: emerging therapeutics?” Nature Reviews Drug Discovery, vol. 9, no. 4, pp. 293–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. E. I. Lichtman, S. M. Helfgott, and M. A. Kriegel, “Emerging therapies for systemic lupus erythematosus—focus on targeting interferon-alpha,” Clinical Immunology, vol. 143, no. 3, pp. 210–221, 2012.